SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-009006
Filing Date
2023-12-21
Accepted
2023-12-21 09:15:09
Documents
12
Period of Report
2023-12-21
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 27401
  Complete submission text file 0001683168-23-009006.txt   201419

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cnsp-20231221.xsd EX-101.SCH 3018
3 XBRL LABEL FILE cnsp-20231221_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE cnsp-20231221_pre.xml EX-101.PRE 22361
6 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3418
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 231503012
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)